The Research Pathology Shared Service at the Arizona Cancer Center (ACC) was established in 1994 to provide routine histology and pathology services for researchers. A developmental Molecular and Cellular Imaging Shared Service began in 1996 under the directorship of Claire Payne, Ph.D., research professor of microbiology and immunology. These two services were combined to make the Molecular and Cellular Pathology Shared Service in 1997 with Thomas Grogan, M.D., professor of pathology, and Dr. Payne as co-directors. The expanded service includes a wide variety of state-of-the-art pathology services and a large inventory of instruments to facilitate automated tissue processing, immunohistochemistry (IHC) and in situ hybridization (ISH). It also includes instrumentation for sophisticated microscopy via confocal, transmission and scanning electron microscopy and image quantitation. The combined laboratories of Drs. Grogan and Payne will provide a wide array of staining and imaging capabilities. The service now includes: 1) animal and human histology services; 2) tissue collection and preservation in a tumor band, including micro-dissection capability; 3) tissue staining including both immunohistochemistry and in situ hybridization with an associated antibody bank; 4) imaging via fluorescence, confocal, transmission and scanning microscopy including digital image acquisition and quantitation via morphometry, apoptosis quantitation and oxidative stress assays; and 5) a consultation service regarding experimental design, assay, imaging methods and interpretation. The merge of the core histology lab with the molecular, cellular imaging lab has resulted in a 50% increase in lab usage, suggesting the newly merged facility has improved efficacy as well as scientific gain.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA023074-22
Application #
6101960
Study Section
Project Start
1999-07-01
Project End
2000-06-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
22
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Arizona
Department
Type
DUNS #
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Berghout, Joanne; Li, Qike; Pouladi, Nima et al. (2018) Single subject transcriptome analysis to identify functionally signed gene set or pathway activity. Pac Symp Biocomput 23:400-411
Kannaiyan, Radhamani; Mahadevan, Daruka (2018) A comprehensive review of protein kinase inhibitors for cancer therapy. Expert Rev Anticancer Ther 18:1249-1270
Weinkauf, Craig C; Concha-Moore, Kirsten; Lindner, Jonathan R et al. (2018) Endothelial vascular cell adhesion molecule 1 is a marker for high-risk carotid plaques and target for ultrasound molecular imaging. J Vasc Surg 68:105S-113S
Xie, Shuwei; Reinecke, James B; Farmer, Trey et al. (2018) Vesicular trafficking plays a role in centriole disengagement and duplication. Mol Biol Cell 29:2622-2631
Rice, Photini F S; Ehrichs, Kevin G; Jones, Mykella S et al. (2018) Does Mutated K-RAS Oncogene Attenuate the Effect of Sulindac in Colon Cancer Chemoprevention? Cancer Prev Res (Phila) 11:16-26
Song, Jin H; Singh, Neha; Luevano, Libia A et al. (2018) Mechanisms Behind Resistance to PI3K Inhibitor Treatment Induced by the PIM Kinase. Mol Cancer Ther 17:2710-2721
Hupple, Clinton W; Morscher, Stefan; Burton, Neal C et al. (2018) A light-fluence-independent method for the quantitative analysis of dynamic contrast-enhanced multispectral optoacoustic tomography (DCE MSOT). Photoacoustics 10:54-64
Padilla-Rodriguez, Marco; Parker, Sara S; Adams, Deanna G et al. (2018) The actin cytoskeletal architecture of estrogen receptor positive breast cancer cells suppresses invasion. Nat Commun 9:2980
Nair, Uma S; Bell, Melanie L; Yuan, Nicole P et al. (2018) Associations Between Comorbid Health Conditions and Quit Outcomes Among Smokers Enrolled in a State Quitline, Arizona, 2011-2016. Public Health Rep 133:200-206
Casillas, Andrea L; Toth, Rachel K; Sainz, Alva G et al. (2018) Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents. Clin Cancer Res 24:169-180

Showing the most recent 10 out of 1336 publications